Advancing the Future of Preclinical Research: Mattek at MPS 2026
Mattek is joining other leaders in biotechnology, pharmaceutical development, and advanced in vitro research to shape the future of human-relevant testing. Connect with us at MPS booth #216 and meet with our team of experts for innovative solutions for safety, efficacy, and translational research.
As industries and regulators continue to advance toward more predictive, non-animal testing strategies, learn how Mattek’s technology supports researchers and product developers with innovative solutions for safety, efficacy, and translational research. Whether you are developing novel therapeutics, ingredients, or consumer products, our team can help guide your testing strategy with scientifically robust, human-relevant approaches.
Meet with an Expert On-Site:
Justin Boyd, Product Manager
Book a Meeting with JustinScientific Poster Presentations
Integration of Incucyte® Workflow and Multi-Organ Toxplate (Kidney, Small Intestine, and Liver) for NAMS-Based Hazard and Risk Assessment of Compounds
Seyoum Ayehunie1, Joeseph Finelli1, Martha Mayo1, Paul Keselman2, Alexander Armento1 1Mattek – Now Part of Sartorius, Ashland, MA, USA. 2Sartorius Stedim North America, Inc., Ann Arbor, MI, USA.
Poster Session 1: May 27, 9:30-11 AM
Background: Advanced primary cell–based 3D human tissue models are a critical component of New Approach Methodologies (NAMs), offering reliable alternatives to animal testing for drug safety assessment. To overcome the limited predictive power of traditional single-organ models, a 3D human Multi-Organ ToxPlate (MOTP) was developed that integrates intestine, liver, and kidney models within a single 96-well plate. The platform was optimized for compatibility with the Sartorius Incucyte® live-cell imaging, enabling high-throughput, real-time toxicity assessment and automated EC50 determination across multiple organ systems simultaneously to the same compound. Methods: Primary human cells representing kidney, intestine, and liver were seeded into the ToxPlate, with 32 wells allocated per tissue type. Cultures were maintained under submerged conditions for three days and then transitioned to air–liquid interface for 12 days to promote differentiation. Tissue reproducibility and barrier integrity were assessed using TEER. Tissues were exposed to known drugs in the presence of a Cytotox Green dye. Live-cell imaging was performed every four hours for 48 hours using the Incucyte® S3 system, and fluorescence intensity was quantified as a measure of cytotoxicity. Results: The Nephrotoxic drug Cisplatin produced EC50 values ranging from 11 to 25 µM, consistent with previously reported data, whereas Oxaliplatin did not induce acute kidney injury at tested concentrations. Multi-drug studies revealed compound-specific and organ-selective toxicity profiles: Cisplatin affected all tissues at higher doses, Fialuridine selectively induced hepatotoxicity, and Troglitazone caused liver and kidney toxicity with variable intestinal effects. In extended dose-range studies in kidney, Cisplatin caused clear dose-dependent reductions in TEER and viability, while Oxaliplatin primarily affected TEER, suggesting TEER is more sensitive for certain compounds. Conclusion: The integrated MOTP–Incucyte® workflow is a robust and reproducible platform for multi-organ drug toxicity testing ideal for early detection of organ-specific toxicity and off-target effects of drugs while reducing animal experimentation.
Request Poster
Use of Patient-Derived 3D Tumoroids Harboring Diverse Mutations to Scaleup Screening of Safety and Efficacy of Metastatic Colorectal Cancer Therapies
Dylan Bryda1, Megan Groves2, Alex Armento1, Anthony Tolcher2, and Seyoum Ayehunie1 1Mattek – Now Part of Sartorius, Ashland, MA, USA. 2Next Oncology, San Antonio, TX, USA.
Poster Session 2: May 27, 3:15-4:45 PM
Background: Patient-derived 3D primary tumoroid (PDPTs) MPS are emerging as physiologically relevant and translational in vitro models for predicting human responses to cancer therapeutics. Compared to conventional 2D cell lines, PDPTs more accurately recapitulate the tumor microenvironment, enable high-throughput drug screening, and support precision medicine. However, widespread adoption has been limited by challenges in large-scale expansion without phenotypic changes. Objective: To develop a highly reproducible and scalable 3D patient-derived tumoroid MPS model for large scale screening of therapeutic safety and efficacy of metastatic colorectal cancer with distinct mutations. Methods: We developed a novel system for in vitro expansion and biobanking of colorectal cancer tumoroids derived from four metastatic colorectal cancer patients with distinct mutations. Our approach integrates matrix-coated plates with microwell technology to scale up tumoroid growth. Two assay platforms were established: (a) 3D Tumoroid MPS generated by seeding 5000 single tumor cells as a stand-alone model, and (b) Complex 3D tissues created by co-seeding 250-500 tumor cells with fibroblasts, endothelial cells, and immune cells to mimic the tumor microenvironment (TME). 3D tumoroids were treated with five chemotherapeutic agents, Cisplatin, Doxorubicin, Oxaliplatin, Fluorouracil, and Cetuximabat at six concentrations each for over a 7-day period (three doses). Results: For tumoroids grown in TME, microscopic and histological analyses confirm uniform-sized tumoroids and glandular-like structures. Epithelial origin and fibroblast presence were validated by CK19+ and vimentin staining, respectively. Live/dead staining using calcein AM and PI revealed dose- and time-dependent drug responses in both platforms. Notably, Doxorubicin, previously unused in these patients, demonstrated significant activity, highlighting the assay’s potential to identify drugs for precision therapy and enable patient-specific drug ranking. Conclusion: Scalable PDPT expansion combined with physiologically relevant assay systems offers a cost-effective, predictive, and non-animal approach for metastatic cancer drug screening, advancing the concept of precision medicine.
Request Poster